Autres langues Scienture Holdings, Inc.

Actions

SCNX

US80880X1046

Produits pharmaceutiques

Temps Différé Nasdaq 21:54:10 19/08/2026			Varia. 5j.	Varia. 1 janv.
0,4784 ^USD	+4,71%		+6,29%	-6,22%

13/08	Scienture Holdings, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/08	Scienture Holdings annonce le lancement commercial et l'exécution des premières commandes de Rezenopy, spray nasal dosé à 10 mg	CI

Autres langues

14/08	SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
14/08	Scienture Holdings: Q2 Earnings Snapshot
13/08	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
12/08	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg
09/07	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers
09/07	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
18/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access
18/06	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team
09/06	SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
04/06	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
02/06	Scienture Secures US Patent Protection for Rezenopy Through 2041
02/06	SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
29/05	Scienture - Eric Sherb resigns as CFO effective May 26, 2026
29/05	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026
18/05	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
15/05	Scienture Holdings: Q1 Earnings Snapshot
15/05	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline
07/05	Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
07/05	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing
06/05	SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
27/04	Scienture Holdings, Inc. announced that it has received $11 million in funding
15/04	Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement